N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Sponsor: Memorial Sloan Kettering Cancer Center • ClinicalTrials.gov ID: NCT05534438

Registry updated: 2026-10-02
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.

Interventions

  • Stereotactic body radiotherapy (Radiation)
    SBRT will be initiated as soon as possible, at not beyond 8 weeks of baseline measurements. Recommended dosing is per department standards for oligometastatic disease (ie, 10 Gy x 3 or 7-8 Gy x 5 fractions daily, excluding weekends and departmental holidays)

Eligibility criteria

Inclusion Criteria: * Age 18 or older * Willing and able to provide informed consent * Metastatic breast cancer, biopsy proven * ER+/HER2-, defined as \>5% ER+ staining * HER2+ (regardless of ER status), including HER2-low and high expressors * History of at least 6 months, sustained response to systemic therapy (clinically or radiographically defined as complete or stable response without progression) * Isolated site of disease progression on FDG PET scan * Consented to 12-245 * ECOG performance status 0-1 Exclusion Criteria: * Pregnancy * Serious medical comorbidity precluding radiation, including connective tissue disorders * Intracranial disease (including previous intracranial involvement) * Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.

Conditions

Oligometastatic Breast Carcinoma Breast Cancer Metastatic Breast Cancer Metastatic Breast Carcinoma ER+ Breast Cancer HER2+ Breast Cancer

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack (Limited Protocol Activities) — Commack, New York, United States
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York, United States
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York, United States
  • Lehigh Valley Health Network (Data Collection Only) — Allentown, Pennsylvania, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record